Expanding the definition of "value" beyond cost, Robert Dubois, MD, PhD, emphasized that clinical pathways need more dynamic quality metrics that provide more than just a snapshot of a patient's performance.
The discussion then moved on to value. Surabhi Dangi-Garimella, PhD, asked the panelists whether clinical pathways can help ensure patients receive high-value care.
Operating on its technical definition where “value” considers both efficacy and cost, Blase Polite, MD, MPP, explained that pathways offer the ability to say “don’t penalize me for doing the right thing for the right patient at the right time.” Being able to go off-pathway allows physicians to avoid therapies with little efficacy but high cost, and decide what is appropriate for the patient.
But if going off-pathway becomes the pattern of care, this is unacceptable, Dr Polite pointed out. Consensus is that pathways are aiming for 80%—not 100% and not 50-60% either.
Pathways ensure that physicians, in a world of bundled payments and alternative payment models, are not penalized for choosing an expensive therapy that makes complete sense for the patient in front of them, Dr Polite said.
Robert Dubois, MD, PhD, however, defined “value” differently, describing it as the benefit a patient derives at what cost. The exact value of pathways is difficult to determine, he said, because pathways are based on a string of pieces of evidence that are essentially just a snapshot. “High value means that the patients are doing well. We assume, based on the snapshots of evidence, that the patients are going to do well,” Dr Dubois said. He however questions whether we currently have the quality measure infrastructure that would ascertain a patient performed better when on a pre-defined treatment pathway.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More